Hemispherx Biopharma Regains Compliance with NYSE MKT Continued Listing Standards

by Barry101 | Sep 19, 2016 | Press Release

PHILADELPHIA, Sept. 19, 2016 — Hemispherx Biopharma (NYSE MKT:HEB) (the “Company”), announced today that, based on a notice received on September 15, 2016 from the New York Stock Exchange, Inc., the Company has regained compliance with the NYSE...

Hemispherx Biopharma to Present at the 18th Annual Rodman & Renshaw Global Investment Conference

by Barry101 | Sep 6, 2016 | Press Release

Recent Articles on Hemispherx Biopharma by BioWorld and Pink Sheet Posted to Corporate WebsitePHILADELPHIA, Sept. 06, 2016 — Hemispherx Biopharma (NYSE MKT:HEB) (the “Company”), announced today that that it will be featured as a presenting company at...

Hemispherx Biopharma, Inc. Announces $5 Million Registered Direct Offering

by Barry101 | Aug 31, 2016 | Press Release

PHILADELPHIA, Aug. 31, 2016 — Hemispherx Biopharma, Inc. (NYSE:HEB) (the “Company” or “Hemispherx”), announced today that it has entered into definitive agreements with two healthcare focused institutional investors for an offering of...

Hemispherx Biopharma to Present Data on the Activity of Ampligen® Against Cancer at CHI’s 4th Annual Immuno-Oncology Summit, August 29 through September 2, 2016 in Boston, MA

by Barry101 | Aug 29, 2016 | Press Release

PHILADELPHIA, Aug. 29, 2016 — Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the “Company” or “Hemispherx”), announced that it will present at CHI’s 4th Annual Immuno-Oncology Summit, August 29 through September 2, 2016 in Boston,...

Hemispherx Biopharma Announces Major Breakthrough: Approval for Commercial Sale of Rintatolimod (U.S. Tradename: Ampligen®) to Treat Severe Cases of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) in the Argentine Republic

by Barry101 | Aug 23, 2016 | Press Release

First Product Approved for ME/CFS Indication Anywhere in the WorldBreakthrough Approval Provides Clear Path for Growth in Latin America and the European UnionPHILADELPHIA, Aug. 23, 2016 — Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the “Company” or...

Hemispherx Biopharma Forms Scientific Advisory Board to Provide Additional Scientific and Pharmaceutical Expertise

by Barry101 | Aug 19, 2016 | Press Release

PHILADELPHIA, Aug. 19, 2016 — Hemispherx Biopharma (NYSE MKT:HEB) announced that it has formed a scientific advisory board (SAB).  The purpose of the SAB is to leverage its member’s scientific and pharmaceutical expertise and advice to advance the...